Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, Piro, Solomon, Martha, Li, Lian-Sheng, Hansen, Rasmus, Rosen, Neal·2016·Science

DOI 10.1126/science.aad6204

Cited by (700)

Items 201–300 of 700

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Ferdinandos Skoulidis, Bob T. Li, Adrianus Johannes De Langen, David S. Hong, H. Léna, Juergen Wolf, Grace Kho Dy, Alessandra Curioni Fontecedro, Pascale Tomasini, Vamsidhar Velcheti et al. · 2025 · Nature Medicine
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Khalil Choucair, Hafsa Imtiaz, Md. Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A. Philip, Bassel El-Rayes, Boris Pasche, Asfar Sohail Azmi · 2025 · Signal Transduction and Targeted Therapy
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation
Jia Lu, Asim K. Bera, Sudershan Reddy Gondi, Kenneth D. Westover · 2017 · Biochemistry
Resistance looms for KRASG12C inhibitors
Hata, Aaron N., Shaw, Alice T. · 2020 · Nature Medicine
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance
Sattler, Martin, Mohanty, Atish, Kulkarni, Prakash, Salgia, Ravi · 2023 · Trends in Cancer
KRAS: Reasons for optimism in lung cancer
Colin R. Lindsay, Mariam Jamal‐Hanjani, Martin David Forster, Fiona Helen Blackhall · 2018 · European Journal of Cancer
The importance of Ras in drug resistance in cancer
Fiona M. Healy, Ian A. Prior, David J. MacEwan · 2021 · British Journal of Pharmacology
Toward a More Precise Future for Oncology
Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases
Khuchtumur Bum‐Erdene, Degang Liu, Giovanni González-Gutiérrez, Mona K. Ghozayel, David Daqiang Xu, Samy O. Meroueh · 2020 · Proceedings of the National Academy of Sciences
Clinical potential of ATM inhibitors
Martin Francis Lavin, Abrey J. Yeo · 2020 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Anna Linehan, Mary O’Reilly, Ray McDermott, Grainne Mary O'Kane · 2024 · Frontiers in Medicine
Pharmacological restoration of GTP hydrolysis by mutant RAS
Antonio Cuevas-Navarro, Yasin Pourfarjam, Feng Hu, Diego J. Rodriguez, Alberto Vides, Ben Sang, Shijie Fan, Yehuda Goldgur, Elisa de Stanchina, Piro Lito · 2024 · Nature
Biological therapies in nonsmall cell lung cancer
Jon Zugazagoitia, Sonia Molina‐Pinelo, Fernando López‐Ríos, Luis G Paz-Ares · 2017 · European Respiratory Journal
A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers
Stephanie L. Guerra, Ophélia Maertens, Ryan Kuzmickas, Thomas De Raedt, Richard O. Adeyemi, Caroline J. Guild, Shawna Guillemette, Amanda J. Redig, Emily S. Chambers, Man Xu et al. · 2020 · Cancer Cell
PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity
Siddiqui, Farid A., Alam, Catharina, Rosenqvist, Petja, Ora, Mikko, Sabt, Ahmed, Manoharan, Ganesh babu, Bindu, Lakshman, Okutachi, Sunday, Catillon, Marie, Taylor, Troy et al. · 2020 · ACS Omega
Irreversibility in dynamical phases and transitions
Daniel S. Seara, Benjamin B. Machta, Michael P. Murrell · 2021 · Nature Communications
KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin
Wen-Hsuan Chang, Thuy‐Tien T. Nguyen, Chia‐Hsin Hsu, Kirsten L. Bryant, Hong Jin Kim, Haoqiang Ying, Jon W. Erickson, Channing J. Der, Richard A. Cerione, Marc A. Antonyak · 2021 · Cancer Letters
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten, Mariano Barbacid · 2021 · Molecular Oncology
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Javier Ros, Caterina Vaghi, Iosune Baraibar, Nadia Saoudi Gonzalez, Marta Rodríguez-Castells, Ariadna García, Adriana Alcaráz, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2024 · International Journal of Molecular Sciences
Mutated RAS: Targeting the “Untargetable” with T Cells
Praveen D. Chatani, James Chih‐Hsin Yang · 2019 · Clinical Cancer Research
Next-generation therapies for pancreatic cancer
Conor W. Buckley, Eileen Mary O'Reilly · 2024 · Expert Review of Gastroenterology & Hepatology
Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms
H Y Lau, Jingyi Tang, Patrick J. Casey, Mei Wang · 2017 · Oncogene
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, Haiwei, Moore, Jill, Malonia, Sunil K., Li, Yingxiang, Ozata, Deniz M., Hough, Soren, Song, Chun-Qing, Smith, Jordan L., Fischer, Andrew, Weng, Zhiping et al. · 2017 · Proceedings of the National Academy of Sciences
Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Gisele Nishiguchi, Alice C. Rico, Huw R. Tanner, Robert J. Aversa, Benjamin R. Taft, Sharadha Subramanian, L Setti, Matthew T. Burger, Lifeng Wan, Victoriano Tamez et al. · 2017 · Journal of Medicinal Chemistry
Blocking Ras inhibition as an antitumor strategy
Nagore I. Marín‐Ramos, Silvia Ortega‐Gutiérrez, María Luz López-Rodríguez · 2018 · Seminars in Cancer Biology
An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
Sunita Shankar, Jean Ching-Yi Tien, Ronald F. Siebenaler, Seema Chugh, Vijaya L. Dommeti, Sylvia Zelenka-Wang, Jessica J. Waninger, Kristin M. Juckette, Alice Xu, Xiao-Ming Wang et al. · 2020 · Nature Communications
Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Tyler D. Hitchman, Gabriella Bayshtok, Emilie Ceraudo, Amanda R. Moore, Cindy Lee, Ruobing Jia, Naitao Wang, Mohini R. Pachai, Alexander Noor Shoushtari, Jasmine H. Francis et al. · 2020 · Clinical Cancer Research
A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas
Neetha Parameswaran, Courtney A. Bartel, Wilnelly M. Hernandez-Sanchez, Kristy L. S. Miskimen, Jacob M. Smigiel, Ahmad Mohammad Khalil, Mark W. Jackson · 2019 · Scientific Reports
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
Rohit Thummalapalli, Ezra Bernstein, Benjamin O. Herzberg, Bob T. Li, Afsheen N. Iqbal, Isabel Ruth Preeshagul, Fernando Costa Santini, Juliana Eng, Marc Ladanyi, Soo‐Ryum Yang et al. · 2023 · JCO Precision Oncology
Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions
Sezen Vatansever, Zeynep Hulya Gumus, Burak Erman · 2016 · Scientific Reports
Targeting KRAS G12C with Covalent Inhibitors
Jonathan M. L. Ostrem, Kevan M. Shokat · 2021 · Annual Review of Cancer Biology
Role of RAS signaling in ovarian cancer
Lubna Therachiyil, Anjana Anand, Abdullah Azmi, Ajaz Ahmad Bhat, Hesham Mohamed Korashy, Shahab Uddin M.S. · 2022 · F1000Research
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Mudasir A. Kumar, Sana Khurshid Baba, Inamu Rashid Khan, Mohd Shahnawaz Khan, Fohad Mabood Husain, Saheem Ahmad, Mohammad Haris, Mayank Singh, Ammira Al‐Shabeeb Akil, Muzafar Ahmad Macha et al. · 2025 · MedComm
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
Wenlin Shao, Yuji M. Mishina, Yunjiang Feng, Giordano Caponigro, Vesselina G. Cooke, Stacy Rivera, Yingyun Wang, Fang Shen, Joshua M. Korn, Lesley A. Mathews Griner et al. · 2018 · Cancer Research
Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic
Savithri Ramurthy, Benjamin R. Taft, Robert J. Aversa, Paul A. Barsanti, Matthew T. Burger, Yan Chun Lou, Gisele Nishiguchi, Alice C. Rico, L Setti, Aaron Smith et al. · 2019 · Journal of Medicinal Chemistry
Efforts to Develop KRAS Inhibitors
Holderfield, Matthew · 2018 · Cold Spring Harbor Perspectives in Medicine
Treating KRAS -mutant NSCLC: latest evidence and clinical consequences
Pilar Garrido, Maria Eugenia Olmedo, Ana Gómez, Luis Paz Ares, Fernando López‐Ríos, Juan Manuel Rosa-Rosa, José Palacios · 2017 · Therapeutic Advances in Medical Oncology
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges
Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello · 2020 · European Journal of Cancer
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients
Umberto Malapelle, Francesco Passiglia, Chiara Cremolini, Maria Lucia Reale, Francesco Pepe, Pasquale Pisapia, Antonio Avallone, Diego Luigi Cortinovis, Alfonso De Stefano, Matteo Fassan et al. · 2021 · European Journal of Cancer
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
Alejandro García‐Álvarez, Carolina Ortiz, Eva Muñoz‐Couselo · 2021 · OncoTargets and Therapy
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Shi, Yuankai, Fang, Jian, Xing, Ligang, Yao, Yu, Zhang, Jian, Liu, Lian, Wang, Yongsheng, Hu, Changlu, Xiong, Jianping, Liu, Zhihua et al. · 2025 · Nature Medicine
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Vincent L. Cannataro, Stephen G. Gaffney, Carly Stender, Zi-Ming Zhao, Mark R. Philips, Andrew E. Greenstein, Jeffrey P. Townsend · 2018 · Oncogene
Precision medicine in pancreatic cancer: treating every patient as an exception
Brian T. Herbst, Lei Zheng · 2019 · The Lancet. Gastroenterology & hepatology
Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations
Rachel A. Burge, G. Aaron Hobbs · 2022 · Advances in cancer research
Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
Yaeger, Rona, Solit, David B. · 2020 · Clinical Cancer Research
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Yi Chen, Qiu-pei Liu, Hua Xie, Jian Ding · 2023 · Acta Pharmacologica Sinica
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, Sandra Vietti Michelina, Pietro Scaparone, Giulio Metro, Andrea De Giglio, Federica Pecci, Giuseppe Lamberti, Chiara Ambrogio et al. · 2023 · Current Oncology Reports
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Priyadarshini Pathak, Gloria Hui Jia Chan, Dustin A. Deming, Cheng Ean Chee · 2024 · American Society of Clinical Oncology Educational Book
Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
Xie, Chun, Li, Ying, Li, Lan-Lan, Fan, Xing-Xing, Wang, Yu-Wei, Wei, Chun-Li, Liu, Liang, Leung, Elaine Lai-Han, Yao, Xiao-Jun · 2017 · Frontiers in Pharmacology
Genomic testing for pancreatic cancer in clinical practice as real-world evidence
Hideyuki Hayashi, Shigeki Tanishima, Kyōkō Fujii, Ryo Mori, Yasunobu Okamura, Emmy Yanagita, Ryosuke Matsuoka, Toraji Amano, Ichiro Kinoshita, Yoshito Komatsu et al. · 2018 · Pancreatology
KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
Gregory D. Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sánchez-Vega, Yuan Liu, James G. Connolly, Yonina R. Murciano‐Goroff, Matthew Joseph Bott, Prasad S. Adusumilli et al. · 2021 · Clinical Cancer Research
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Rémy Nicolle, Jerome F. Cros, Louis de Mestier, Jean‐Baptiste Bachet, Pascal R. Hammel · 2022 · Therapeutic Advances in Medical Oncology
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Christina Chen, Xin Liu, Che‐Yu Chang, Helen Y. Wang, Rong‐Fu Wang · 2023 · Genes
KRAS: A Promising Therapeutic Target for Cancer Treatment
Hai-zhou Wu, Jiaqi Xiao, Songshu Xiao, Yan Cheng · 2019 · Current Topics in Medicinal Chemistry
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
Ji, Jingran, Wang, Chongkai, Fakih, Marwan · 2022 · OncoTargets and Therapy
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer
Kitai, Hidenori, Choi, Philip H., Yang, Yu C., Boyer, Jacob A., Whaley, Adele, Pancholi, Priya, Thant, Claire, Reiter, Jason, Chen, Kevin, Markov, Vladimir et al. · 2024 · Nature Communications
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, Simon Manuel, Burge, Matthew E., Whitehall, Vicki L. J. · 2023 · Cancers
Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling
Shuhui Lim, Nicolas C. Boyer, Nicole Boo, Chunhui Huang, Gireedhar Venkatachalam, Yu-Chi Angela Juang, Michael Garrigou, Hung Yi Kristal Kaan, Ruchia Duggal, Khong Ming Peh et al. · 2021 · Chemical Science
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, Cheng Chen, Jia Wang, Wenqian Wang, Haopeng Rui, Jingtao Lu, Shun Lü, Tony S.K. Mok et al. · 2024 · Cancer Discovery
KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry
Jia Lu, Rane A. Harrison, Lianbo Li, Mei Zeng, Sudershan Reddy Gondi, David A. Scott, Nathanael S. Gray, John R. Engen, Kenneth D. Westover · 2017 · Structure
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Emily Nicole Arner, Wenting Du, Rolf A. Brekken · 2019 · Frontiers in Oncology
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang · 2023 · Experimental Hematology and Oncology
Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching
Rane A. Harrison, Jia Lu, Martin A. Carrasco, John Hunter, Anuj Manandhar, Sudershan Reddy Gondi, Kenneth D. Westover, John R. Engen · 2016 · Journal of Molecular Biology
Reactive chemistry for covalent probe and therapeutic development
R. Justin Grams, Ku‐Lung Hsu · 2022 · Trends in Pharmacological Sciences
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
Hang Sheng Yang, Xinyi Zhou, Dongliang Fu, Chenqin Le, Jiafeng Wang, Quan Zhou, Xiangrui Liu, Ying Yuan, Kefeng Ding, Qian Xiao · 2022 · 癌症：英文版
Regulation of large and small G proteins by ubiquitination
Henrik Gunnar Dohlman, Sharon L. Campbell · 2019 · Journal of Biological Chemistry
Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics
Daniel Y. Yoo, Andrew D. Hauser, Stephen T. Joy, Dafna Bar‐Sagi, Paramjit S. Arora · 2020 · ACS Chemical Biology
A single inhibitor for all KRAS mutations
Ryan Bruce Corcoran · 2023 · Nature Cancer
Energy dissipation and fluctuations in a driven liquid
Clara del Junco, Laura Tociu, Suriyanarayanan Vaikuntanathan · 2018 · Proceedings of the National Academy of Sciences
Targeting KRAS in Colorectal Cancer
Chongkai Wang, Marwan Fakih · 2021 · Current Oncology Reports
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Natsuki Osaka, Yoshihisa Hirota, Doshun Ito, Yoshiki Ikeda, Ryo Kamata, Yuki Fujii, Venkat R. Chirasani, Sharon L. Campbell, Koh Takeuchi, Toshiya Senda et al. · 2021 · Frontiers in Molecular Biosciences
Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors
Meiying Liu, Guizhen Zhou, Wenhong Su, Yuejiao Gu, Mingshan Gao, Kun Wang, Ruifeng Huo, Yupeng Li, Zehui Zhou, Kaixian Chen et al. · 2023 · ACS Medicinal Chemistry Letters
MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells
Huanji Xu, Sheng Zhou, Hongwei Xia, Huangfei Yu, Qiulin Tang, Feng Bi · 2019 · Cell Death and Differentiation
RAS pathway regulation in melanoma
Amira Al Mahi, Julien Ablain · 2022 · Disease Models & Mechanisms
KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Nastaran Karimi, Seyed Javad Moghaddam · 2023 · Cells
Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens
Shonan Sho, Colin M. Court, Stephen H. Kim, David R. Braxton, Shuang Hou, V. Raman Muthusamy, Rabindra R. Watson, Alireza Sedarat, Hsian‐Rong Tseng, James S. Tomlinson · 2017 · PLoS ONE
Targeting the α4-α5 interface of RAS results in multiple levels of inhibition
Russell Spencer-Smith, Lie Li, Sheela Prasad, Akiko Koide, Shohei Koide, John P. O’Bryan · 2017 · Small GTPases
Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease
Christopher M. Gromisch, Motaz Qadan, Mariana Albuquerque Machado, Kebin Liu, Yolonda Lorig Colson, Mark W. Grinstaff · 2020 · Cancer Research
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Rong Du, Delaney K. Sullivan, Nancy G. Azizian, Yuanhui Liu, Yulin Li · 2021 · BMC Cancer
Targeting RAS oncogenesis with SOS1 inhibitors
Roman Christian Hillig, Benjamin Bader · 2022 · Advances in cancer research
RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics
Walaa E. Kattan, John F. Hancock · 2020 · Biochemical Journal
The kinase PLK1 promotes the development of Kras / Tp53 -mutant lung adenocarcinoma through transcriptional activation of the receptor RET
Yifan Kong, Derek B. Allison, Qiongsi Zhang, Daheng He, Yuntong Li, Fengyi Mao, Chaohao Li, Zhiguo Li, Yanquan Zhang, Jianlin Wang et al. · 2022 · Science Signaling
Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale · 2023 · Drug Discovery Today
Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo
Zhongwei Liu, Weimin Gao · 2019 · Archives of Toxicology
Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders
Federica D’Aria, Vincenzo Maria D’Amore, Francesco Saverio Di Leva, Jussara Amato, Marco Caterino, Pasquale Russomanno, Silvia Salerno, Elisabetta Barresi, Marinella De Leo, Anna María Marini et al. · 2020 · European Journal of Pharmaceutical Sciences
Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study
Betzabel N. Cajiao Garcia, Léon C.L.T. van Kempen, Chantal C. H. J. Kuijpers, Ed M. D. Schuuring, Stefan M. Willems, Anthonie J. van der Wekken · 2022 · Lung Cancer
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
Prasanna Srinivasan Ramalingam, Purushothaman Balakrishnan, Senthilnathan Rajendran, Arunachalam Jothi, Ramalingam Rajasekaran, Sivakumar Arumugam · 2023 · Current Issues in Molecular Biology
Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro
Yihe Wu, Jinming Xu, Jinbo Chen, Meirong Zou, Aizemaiti Rusidanmu, Rong Yang · 2017 · Thoracic Cancer
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, Wenjuan, Marti, Thomas M., Dorn, Patrick, Peng, Ren-Wang · 2022 · Frontiers in Oncology
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Xiaoxiao Liu, Zhang Li, Yuexiang Wang · 2021 · Advanced Biology
Therapeutic Targets of KRAS in Colorectal Cancer
Rahman, Shafia, Garrel, Shimon, Gerber, Michael, Maitra, Radhashree, Goel, Sanjay · 2021 · Cancers
From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
Mahsa Saliani, Razieh Jalal, Mohammad Reza Ahmadian · 2019 · Cancer Biology and Medicine
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
Hidenori Kitai, Hiromichi Ebi · 2016 · Small GTPases
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
Enrico Gurreri, Giannicola Genovese, Luigi Perelli, Antonio Agostini, Geny Piro, Carmine Carbone, Giampaolo Tortora · 2023 · International Journal of Molecular Sciences
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Kinga Nyíri, Gergely Koppány, Beáta G. Vértessy · 2020 · Cancer and Metastasis Reviews
Targeting mutant KRAS
Daniel A. Erlanson, Kevin R. Webster · 2021 · Current Opinion in Chemical Biology
Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS G12C and ARS compounds
Maria G. Khrenova, Anna M. Kulakova, Alexander V. Nemukhin · 2020 · Organic & Biomolecular Chemistry
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, Johannes Popow, Florian Ebner, Daniel Gerlach, Antonia Geyer, Valeria Santoro, Andrew S. Boghossian, Matthew G. Rees et al. · 2024 · Molecular Cancer Therapeutics
New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism
Mjriam Capula, Giulia Mantini, Niccola Funel, Elisa Giovannetti · 2019 · Expert Review of Clinical Pharmacology
Genome-wide DNA methylation analysis of KRAS mutant cell lines
Ben Yi Tew, Joel K. Durand, Kirsten L. Bryant, Tikvah K. Hayes, Sen Peng, Nhan L. Tran, Gerald C. Gooden, David N. Buckley, Channing J. Der, Albert S. Baldwin et al. · 2020 · Scientific Reports